All Articles

Endometrial and ovarian cancers are the sixth and seventh most common cancers in women worldwide.

Symptoms that patients with cancer experience, either due to their illness or as a result of cancer treatment, are known to diminish their health-related quality of life.

Significantly improved outcomes with D+T vs BRAF inhibitor (BRAFi) monotherapy have been demonstrated in phase 3 BRAF V600E/K–mutant melanoma trials (COMBI-d [NCT01584648]; COMBI-v [NCT01597908]), supporting use of D+T as a treatment for this disease.

Ibrutinib, a B-cell receptor pathway inhibitor, is approved in the United States for the treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and allows for treatment without chemotherapy.

Chimeric antigen receptor (CAR) T cells are engineered from a patient’s own immune cells to redirect them to attack tumor cells.

Breast cancer occurs predominantly in older, postmenopausal women (>50 years), although the incidence of ABC in younger, premenopausal women is increasing.

To honor our connection to the field of breast cancer, we dedicate a special annual edition of JONS to breast cancer and the strides being made in the treatment of this disease as part of our Best Practices series.

A breast cancer diagnosis can be difficult for women of any age, but young women can have unique needs that make this experience more complex.

A breast nurse navigator can perform patient-centered education on breast cancer type and possible treatment options using the inclusive pathology report, as well as be available during the disease trajectory to proactively guide the patient with additional education and support.

Intercepting, translating, consoling, advocating, and smoothing the rocky road for breast cancer patients, nurse navigators are the linchpins for cancer patients from diagnosis through treatment. These are some of the nurse navigators whom patients encounter on their journey.